

09/993,295
1/5/05 Wook

d his

(FILE 'HOME' ENTERED AT 09:24:47 ON 05 JAN 2005)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, CANCERLIT, JAPIO' ENTERED AT
09:25:08 ON 05 JAN 2005

L1 1694 S (INTER ALPHA TRYPSIN INHIBITOR)
L2 1 S L1 AND (INSULIN RESISTANCE)
L3 6 S L1 AND DIABETE?
L4 21 S L1 AND INSULIN?
L5 5 S L3 AND L4
L6 2 DUPLICATE REMOVE L5 (3 DUPLICATES REMOVED)
L7 86 S L1 AND MARKER?
L8 24 S L7 AND DIAGNOS?
L9 20 DUPLICATE REMOVE L8 (4 DUPLICATES REMOVED)

=>

d his

(FILE 'HOME' ENTERED AT 09:24:47 ON 05 JAN 2005)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, CANCERLIT, JAPIO' ENTERED AT
09:25:08 ON 05 JAN 2005

L1	1694 S (INTER ALPHA TRYPSIN INHIBITOR)
L2	1 S L1 AND (INSULIN RESISTANCE)
L3	6 S L1 AND DIABETE?
L4	21 S L1 AND INSULIN?
L5	5 S L3 AND L4
L6	2 DUPLICATE REMOVE L5 (3 DUPLICATES REMOVED)
L7	86 S L1 AND MARKER?
L8	24 S L7 AND DIAGNOS?
L9	20 DUPLICATE REMOVE L8 (4 DUPLICATES REMOVED)

=>

ANSWER 13 OF 20 JAPIO (C) 2005 JPO on STN
AN 1997-159668 JAPIO
TI **DIAGNOSTIC KIT FOR FIBRILLATION OF LIVER**
IN UCHIDA KAZUO
PA IKAGAKU:KK
PI JP 09159668 A 19970620 Heisei
AI JP 1995-346521 (JP07346521 Heisei) 19951211
PRAI JP 1995-346521 19951211
SO PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined Applications, Vol. 1997
IC ICM G01N033-50
ICS G01N033-53
AB PROBLEM TO BE SOLVED: To **diagnose** fibrillation of liver and
productivity of protein by measuring **inter-α
trypsin inhibitor** in blood.
SOLUTION: **Inter-α trypsin
inhibitor** in blood is selected as an object to be measured. The
inter-α trypsin inhibitor is a
protein produced only in liver cell and one of the extracellular matrix
components of liver servable as a fibrillation **marker** of liver.
Production of **inter-α trypsin
inhibitor** in blood is reduced as the fibrillation of liver
progresses and the concentration of **inter-α
trypsin inhibitor** in blood can be discriminated clearly
between a healthy person and a hepatocirrhosis patient. The **inter
-α trypsin inhibitor** is invariant for
various inflammatory diseases and reflects only the fibrillation of liver.
Concentration **inter-α trypsin
inhibitor** in blood can be measured conveniently by a routine
method and the **inter-α trypsin
inhibitor** also reflects productivity of protein of liver because
it is produced only from the liver cell.
COPYRIGHT: (C)1997,JPO

ANSWER 16 OF 20 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on
 STN
 AN 1991:327839 BIOSIS
 DN PREV199141024389; BR41:24389
 TI ARE ALPHA-1 ANTICHYMOTRYPSIN AND **INTER-ALPHA
 TRYPSIN INHIBITOR** PERIPHERAL **MARKERS** OF
 ALZHEIMER'S DISEASE.
 AU FURBY A [Reprint author]; LEYS D; DELACOURTE A; BUEE L; SOETAERT G; PETIT
 H
 CS DEP NEUROL, INSERM U156, CHRU DE LILLE, HOPITAL B, 59037 LILLE, FR
 SO Journal of Neurology Neurosurgery and Psychiatry, (1991) Vol. 54, No. 5,
 pp. 469.
 CODEN: JNNPAU. ISSN: 0022-3050.
 DT Article
 FS BR
 LA ENGLISH
 ED Entered STN: 20 Jul 1991
 Last Updated on STN: 20 Jul 1991
 CC Behavioral biology - Human behavior 07004
 Biochemistry methods - Proteins, peptides and amino acids 10054
 Biochemistry studies - Proteins, peptides and amino acids 10064
 Pathology - Diagnostic 12504
 Metabolism - Proteins, peptides and amino acids 13012
 Blood - Blood and lymph studies 15002
 Blood - Other body fluids 15010
 Nervous system - General and methods 20501
 Nervous system - Pathology 20506
 Psychiatry - Psychopathology, psychodynamics and therapy 21002
 IT Major Concepts
 Behavior; Biochemistry and Molecular Biophysics; Blood and Lymphatics
 (Transport and Circulation); Metabolism; Neurology (Human Medicine,
 Medical Sciences); Pathology; Physiology; Psychiatry (Human Medicine,
 Medical Sciences)
 IT Miscellaneous Descriptors
 HUMAN SERUM CEREBROSPINAL FLUID DEMENTIA **DIAGNOSIS**
 ORGN Classifier
 Hominidae 86215
 Super Taxa
 Primates; Mammalia; Vertebrata; Chordata; Animalia
 Taxa Notes
 Animals, Chordates, Humans, Mammals, Primates, Vertebrates
 RN 39346-44-6 (**INTER-ALPHA-TRYPSIN
 INHIBITOR**)

AN 2004:74536 BIOSIS
DN PREV200400077774
TI **Inter-alpha-trypsin inhibitor** as a
marker for sepsis.
AU Lim, Yow-Pin [Inventor, Reprint Author]; Hixson, Douglas C. [Inventor]
CS ASSIGNEE: Rhode Island Hospital
PI US 6660482 December 09, 2003
SO Official Gazette of the United States Patent and Trademark Office Patents,
(Dec 9 2003) Vol. 1277, No. 2. <http://www.uspto.gov/web/menu/patdata.html>.
e-file.
ISSN: 0098-1133 (ISSN print).
DT Patent
LA English
ED Entered STN: 4 Feb 2004
Last Updated on STN: 4 Feb 2004
AB The invention provides a method of **diagnosing** sepsis in a mammal
by contacting a bodily fluid from the mammal with a ligand which binds to
an **inter-alpha trypsin inhibitor**
(ITI) polypeptide under conditions sufficient to form an ITI-ligand
complex and detecting the complex.
NCL 435071000
CC Biochemistry studies - General 10060
Pathology - Diagnostic 12504
Medical and clinical microbiology - General and methods 36001
IT Major Concepts
Biochemistry and Molecular Biophysics; Infection
IT Diseases
sepsis: bacterial disease, infectious disease, **diagnosis**
Sepsis (MeSH)
IT Chemicals & Biochemicals
inter-alpha trypsin inhibitor
-ligand complex; **inter-alpha-trypsin**
inhibitor polypeptide

AN 2004:672718 CAPLUS
DN 141:222928
ED Entered STN: 18 Aug 2004
TI Three Biomarkers Identified from Serum Proteomic Analysis for the
Detection of Early Stage Ovarian Cancer
AU Zhang, Zhen; Bast, Robert C., Jr.; Yu, Yinhua; Li, Jinong; Sokoll, Lori
J.; Rai, Alex J.; Rosenzweig, Jason M.; Cameron, Bonnie; Wang, Young Y.;
Meng, Xiao-Ying; Berchuck, Andrew; van Haaften-Day, Carolien; Hacker,
Neville F.; de Bruijn, Henk W. A.; van der Zee, Ate G. J.; Jacobs, Ian J.;
Fung, Eric T.; Chan, Daniel W.
CS Department of Pathology, Biomarker Discovery Center, Johns Hopkins Medical
Institutions, Baltimore, MD, USA
SO Cancer Research (2004), 64(16), 5882-5890
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
CC 14-1 (Mammalian Pathological Biochemistry)
AB Early detection remains the most promising approach to improve long-term
survival of patients with ovarian cancer. In a five-center case-control
study, serum proteomic expressions were analyzed on 153 patients with
invasive epithelial ovarian cancer, 42 with other ovarian cancers, 166
with benign pelvic masses, and 142 healthy women. Data from patients with
early stage ovarian cancer and healthy women at two centers were analyzed
independently and the results cross-validated to discover potential
biomarkers. The results were validated using the samples from two of the
remaining centers. After protein identification, biomarkers for which an
immunoassay was available were tested on samples from the fifth center,
which included 41 healthy women, 41 patients with ovarian cancer, and 20
each with breast, colon, and prostate cancers. Three biomarkers were
identified as follows: (a) apolipoprotein A1 (down-regulated in cancer);
(b) a truncated form of transthyretin (down-regulated); and (c) a cleavage
fragment of inter-.alpha.-trypsin
inhibitor heavy chain H4 (up-regulated). In independent
validation to detect early stage invasive epithelial ovarian cancer from
healthy controls, the sensitivity of a multivariate model combining the
three biomarkers and CA125 [74% (95% CI, 52-90%)] was higher than that of
CA125 alone [65% (95% CI, 43-84%)] at a matched specificity of 97% (95%
CI, 89-100%). When compared at a fixed sensitivity of 83% (95% CI,
61-95%), the specificity of the model [94% (95% CI, 85-98%)] was
significantly better than that of CA125 alone [52% (95% CI, 39-65%)].
These biomarkers demonstrated the potential to improve the detection of
early stage ovarian cancer.
ST **inter alpha trypsin inhibitor**
heavy chain biomarker ovarian cancer; transthyretin apolipoprotein A1
biomarker ovarian cancer **diagnosis**
IT Apolipoproteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); BIOL
(Biological study); USES (Uses)
(A-I; three biomarkers identified from serum proteomic anal. for
detection of early stage ovarian cancer)
IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); BIOL
(Biological study); USES (Uses)
(SHAP (serum-derived hyaluronan-associated protein); three biomarkers
identified from serum proteomic anal. for detection of early stage
ovarian cancer)
IT **Diagnosis**
(cancer; three biomarkers identified from serum proteomic anal. for
detection of early stage ovarian cancer)
IT Ovary, neoplasm

(carcinoma; three biomarkers identified from serum proteomic anal. for detection of early stage ovarian cancer)

IT Blood serum

Human

Tumor **markers**

(three biomarkers identified from serum proteomic anal. for detection of early stage ovarian cancer)

IT Transthyretin

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)

(three biomarkers identified from serum proteomic anal. for detection of early stage ovarian cancer)

RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Adam, B; Cancer Res 2002, V62, P3609 CAPLUS
- (2) Bachorik, P; Clin Chem 1997, V43, P2364 CAPLUS
- (3) Baggerly, K; Bioinformatics 2004, V20, P777 CAPLUS
- (4) Banez, L; J Urol 2003, V170, P442 CAPLUS
- (5) Bast, R; Int J Biol Markers 1998, V13, P179 CAPLUS
- (6) Coussens, L; Nature (Lond) 2002, V420, P860 CAPLUS
- (7) Cvetkovic, D; Clin Cancer Res 2003, V9, P1013 CAPLUS
- (8) Diamandis, E; Clin Chem 2002, V48, P1198 CAPLUS
- (9) Diamandis, E; J Natl Cancer Inst (Bethesda) 2004, V96, P353
- (10) Diamandis, E; Lancet 2002, V360, P170 MEDLINE
- (11) Diamandis, E; Mol Cell Proteomics 2004, V3, P367 CAPLUS
- (12) Fung, E; Curr Opin Biotechnol 2001, V12, P65 CAPLUS
- (13) Giordano, T; Am J Pathol 2001, V159, P1231 MEDLINE
- (14) Hayashi, H; Gynecol Obstet Investig 1999, V47, P58 MEDLINE
- (15) Hutchens, T; Rapid Commun Mass Spectrom 1993, V7, P576 CAPLUS
- (16) Jacobs, I; Hum Reprod 1989, V4, P1 CAPLUS
- (17) Jacobs, I; Lancet 1999, V353, P1207 MEDLINE
- (18) Jemal, A; CA - Cancer J Clin 2002, V52, P23
- (19) Jungner, I; Clin Chem 1998, V44, P1641 CAPLUS
- (20) Kozak, K; Proc Natl Acad Sci USA 2003, V100, P12343 CAPLUS
- (21) Kuesel, A; Int J Cancer 1992, V52, P341 CAPLUS
- (22) Lawrie, L; Mol Pathol 2001, V54, P253 CAPLUS
- (23) Li, J; Clin Chem 2002, V48, P1296 CAPLUS
- (24) Mahlck, C; Gynecol Obstet Investig 1994, V37, P135 MEDLINE
- (25) Matrisian, L; Cancer Res 2003, V63, P6105 CAPLUS
- (26) Menon, U; Best Pract Res Clin Obstet Gynaecol 2002, V16, P469
- (27) Metz, C; Semin Nucl Med 1978, V8, P283 MEDLINE
- (28) Mok, S; J Natl Cancer Inst (Bethesda) 2001, V93, P1458 CAPLUS
- (29) Nishimura, H; FEBS Lett 1995, V357, P207 CAPLUS
- (30) Petricoin, E; J Natl Cancer Inst 2002, V94, P1576 CAPLUS
- (31) Petricoin, E; Lancet 2002, V359, P572 CAPLUS
- (32) Pu, X; Biochim Biophys Acta 1994, V1208, P338 CAPLUS
- (33) Qu, Y; Clin Chem 2002, V48, P1835 CAPLUS
- (34) Rai, A; Arch Pathol Lab Med 2002, V126, P1518 CAPLUS
- (35) Roberts, D; DNA Cell Biol 2002, V21, P11 CAPLUS
- (36) Rosenwald, A; N Engl J Med 2002, V346, P1937
- (37) Skates, S; J Am Stat Assoc 2001, V96, P429
- (38) van Bennekum, A; J Biol Chem 2001, V276, P1107 CAPLUS
- (39) van Haaften-Day, C; Cancer (Phila) 2001, V92, P2837 CAPLUS
- (40) van Nagell, J; Gynecol Oncol 2000, V77, P350
- (41) van de Vijver, M; N Engl J Med 2002, V347, P1999 CAPLUS
- (42) Vapnik, V; Statistical learning theory 1998, P736
- (43) Vlahou, A; Am J Pathol 2001, V158, P1491 CAPLUS
- (44) Woolas, R; Gynecol Oncol 1995, V59, P111 MEDLINE
- (45) Yousef, G; Cancer Res 2003, V63, P2223 CAPLUS
- (46) Yousef, G; Endocr Rev 2001, V22, P184 CAPLUS
- (47) Yousef, G; Minerva Endocrinol 2002, V27, P157 MEDLINE
- (48) Zhang, Z; Gynecol Oncol 1999, V73, P56 MEDLINE

- (49) Zhang, Z; Methods of microarray data analysis: papers from CAMDA '00 2001,
P125 CAPLUS
- (50) Zhang, Z; Microarray data analysis II: papers from CAMDA '01 2002

AN 2004:672718 CAPLUS
DN 141:222928
ED Entered STN: 18 Aug 2004
TI Three Biomarkers Identified from Serum Proteomic Analysis for the
Detection of Early Stage Ovarian Cancer
AU Zhang, Zhen; Bast, Robert C., Jr.; Yu, Yinhua; Li, Jinong; Sokoll, Lori
J.; Rai, Alex J.; Rosenzweig, Jason M.; Cameron, Bonnie; Wang, Young Y.;
Meng, Xiao-Ying; Berchuck, Andrew; van Haaften-Day, Carolien; Hacker,
Neville F.; de Bruijn, Henk W. A.; van der Zee, Ate G. J.; Jacobs, Ian J.;
Fung, Eric T.; Chan, Daniel W.
CS Department of Pathology, Biomarker Discovery Center, Johns Hopkins Medical
Institutions, Baltimore, MD, USA
SO Cancer Research (2004), 64(16), 5882-5890
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
CC 14-1 (Mammalian Pathological Biochemistry)
AB Early detection remains the most promising approach to improve long-term
survival of patients with ovarian cancer. In a five-center case-control
study, serum proteomic expressions were analyzed on 153 patients with
invasive epithelial ovarian cancer, 42 with other ovarian cancers, 166
with benign pelvic masses, and 142 healthy women. Data from patients with
early stage ovarian cancer and healthy women at two centers were analyzed
independently and the results cross-validated to discover potential
biomarkers. The results were validated using the samples from two of the
remaining centers. After protein identification, biomarkers for which an
immunoassay was available were tested on samples from the fifth center,
which included 41 healthy women, 41 patients with ovarian cancer, and 20
each with breast, colon, and prostate cancers. Three biomarkers were
identified as follows: (a) apolipoprotein A1 (down-regulated in cancer);
(b) a truncated form of transthyretin (down-regulated); and (c) a cleavage
fragment of **inter-.alpha.-trypsin**
inhibitor heavy chain H4 (up-regulated). In independent
validation to detect early stage invasive epithelial ovarian cancer from
healthy controls, the sensitivity of a multivariate model combining the
three biomarkers and CA125 [74% (95% CI, 52-90%)] was higher than that of
CA125 alone [65% (95% CI, 43-84%)] at a matched specificity of 97% (95%
CI, 89-100%). When compared at a fixed sensitivity of 83% (95% CI,
61-95%), the specificity of the model [94% (95% CI, 85-98%)] was
significantly better than that of CA125 alone [52% (95% CI, 39-65%)].
These biomarkers demonstrated the potential to improve the detection of
early stage ovarian cancer.
ST **inter alpha trypsin inhibitor**
heavy chain biomarker ovarian cancer; transthyretin apolipoprotein A1
biomarker ovarian cancer **diagnosis**
IT Apolipoproteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); BIOL
(Biological study); USES (Uses)
(A-I; three biomarkers identified from serum proteomic anal. for
detection of early stage ovarian cancer)
IT Proteins
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); BIOL
(Biological study); USES (Uses)
(SHAP (serum-derived hyaluronan-associated protein); three biomarkers
identified from serum proteomic anal. for detection of early stage
ovarian cancer)
IT **Diagnosis**
(cancer; three biomarkers identified from serum proteomic anal. for
detection of early stage ovarian cancer)
IT Ovary, neoplasm

(carcinoma; three biomarkers identified from serum proteomic anal. for detection of early stage ovarian cancer)

IT Blood serum

Human

Tumor **markers**

(three biomarkers identified from serum proteomic anal. for detection of early stage ovarian cancer)

IT Transthyretin

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)

(three biomarkers identified from serum proteomic anal. for detection of early stage ovarian cancer)

RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Adam, B; Cancer Res 2002, V62, P3609 CAPLUS
- (2) Bachorik, P; Clin Chem 1997, V43, P2364 CAPLUS
- (3) Baggerly, K; Bioinformatics 2004, V20, P777 CAPLUS
- (4) Banez, L; J Urol 2003, V170, P442 CAPLUS
- (5) Bast, R; Int J Biol Markers 1998, V13, P179 CAPLUS
- (6) Coussens, L; Nature (Lond) 2002, V420, P860 CAPLUS
- (7) Cvetkovic, D; Clin Cancer Res 2003, V9, P1013 CAPLUS
- (8) Diamandis, E; Clin Chem 2002, V48, P1198 CAPLUS
- (9) Diamandis, E; J Natl Cancer Inst (Bethesda) 2004, V96, P353
- (10) Diamandis, E; Lancet 2002, V360, P170 MEDLINE
- (11) Diamandis, E; Mol Cell Proteomics 2004, V3, P367 CAPLUS
- (12) Fung, E; Curr Opin Biotechnol 2001, V12, P65 CAPLUS
- (13) Giordano, T; Am J Pathol 2001, V159, P1231 MEDLINE
- (14) Hayashi, H; Gynecol Obstet Investig 1999, V47, P58 MEDLINE
- (15) Hutchens, T; Rapid Commun Mass Spectrom 1993, V7, P576 CAPLUS
- (16) Jacobs, I; Hum Reprod 1989, V4, P1 CAPLUS
- (17) Jacobs, I; Lancet 1999, V353, P1207 MEDLINE
- (18) Jemal, A; CA - Cancer J Clin 2002, V52, P23
- (19) Jungner, I; Clin Chem 1998, V44, P1641 CAPLUS
- (20) Kozak, K; Proc Natl Acad Sci USA 2003, V100, P12343 CAPLUS
- (21) Kuesel, A; Int J Cancer 1992, V52, P341 CAPLUS
- (22) Lawrie, L; Mol Pathol 2001, V54, P253 CAPLUS
- (23) Li, J; Clin Chem 2002, V48, P1296 CAPLUS
- (24) Mahlck, C; Gynecol Obstet Investig 1994, V37, P135 MEDLINE
- (25) Matrisian, L; Cancer Res 2003, V63, P6105 CAPLUS
- (26) Menon, U; Best Pract Res Clin Obstet Gynaecol 2002, V16, P469
- (27) Metz, C; Semin Nucl Med 1978, V8, P283 MEDLINE
- (28) Mok, S; J Natl Cancer Inst (Bethesda) 2001, V93, P1458 CAPLUS
- (29) Nishimura, H; FEBS Lett 1995, V357, P207 CAPLUS
- (30) Petricoin, E; J Natl Cancer Inst 2002, V94, P1576 CAPLUS
- (31) Petricoin, E; Lancet 2002, V359, P572 CAPLUS
- (32) Pu, X; Biochim Biophys Acta 1994, V1208, P338 CAPLUS
- (33) Qu, Y; Clin Chem 2002, V48, P1835 CAPLUS
- (34) Rai, A; Arch Pathol Lab Med 2002, V126, P1518 CAPLUS
- (35) Roberts, D; DNA Cell Biol 2002, V21, P11 CAPLUS
- (36) Rosenwald, A; N Engl J Med 2002, V346, P1937
- (37) Skates, S; J Am Stat Assoc 2001, V96, P429
- (38) van Bennekum, A; J Biol Chem 2001, V276, P1107 CAPLUS
- (39) van Haaften-Day, C; Cancer (Phila) 2001, V92, P2837 CAPLUS
- (40) van Nagell, J; Gynecol Oncol 2000, V77, P350
- (41) van de Vijver, M; N Engl J Med 2002, V347, P1999 CAPLUS
- (42) Vapnik, V; Statistical learning theory 1998, P736
- (43) Vlahou, A; Am J Pathol 2001, V158, P1491 CAPLUS
- (44) Woolas, R; Gynecol Oncol 1995, V59, P111 MEDLINE
- (45) Yousef, G; Cancer Res 2003, V63, P2223 CAPLUS
- (46) Yousef, G; Endocr Rev 2001, V22, P184 CAPLUS
- (47) Yousef, G; Minerva Endocrinol 2002, V27, P157 MEDLINE
- (48) Zhang, Z; Gynecol Oncol 1999, V73, P56 MEDLINE

- (49) Zhang, Z; Methods of microarray data analysis: papers from CAMDA '00 2001,
P125 CAPLUS
- (50) Zhang, Z; Microarray data analysis II: papers from CAMDA '01 2002

ANSWER 16 OF 20 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation. on
 STN
 AN 1991:327839 BIOSIS
 DN PREV199141024389; BR41:24389
 TI ARE ALPHA-1 ANTICHYMOTRYPSIN AND **INTER-ALPHA
 TRYPSIN INHIBITOR** PERIPHERAL **MARKERS** OF
 ALZHEIMER'S DISEASE.
 AU FURBY A [Reprint author]; LEYS D; DELACOURTE A; BUEE L; SOETAERT G; PETIT
 H
 CS DEP NEUROL, INSERM U156, CHRU DE LILLE, HOPITAL B, 59037 LILLE, FR
 SO Journal of Neurology Neurosurgery and Psychiatry, (1991) Vol. 54, No. 5,
 pp. 469.
 CODEN: JNNPAU. ISSN: 0022-3050.
 DT Article
 FS BR
 LA ENGLISH
 ED Entered STN: 20 Jul 1991
 Last Updated on STN: 20 Jul 1991
 CC Behavioral biology - Human behavior 07004
 Biochemistry methods - Proteins, peptides and amino acids 10054
 Biochemistry studies - Proteins, peptides and amino acids 10064
 Pathology - Diagnostic 12504
 Metabolism - Proteins, peptides and amino acids 13012
 Blood - Blood and lymph studies 15002
 Blood - Other body fluids 15010
 Nervous system - General and methods 20501
 Nervous system - Pathology 20506
 Psychiatry - Psychopathology, psychodynamics and therapy 21002
 IT Major Concepts
 Behavior; Biochemistry and Molecular Biophysics; Blood and Lymphatics
 (Transport and Circulation); Metabolism; Neurology (Human Medicine,
 Medical Sciences); Pathology; Physiology; Psychiatry (Human Medicine,
 Medical Sciences)
 IT Miscellaneous Descriptors
 HUMAN SERUM CEREBROSPINAL FLUID DEMENTIA **DIAGNOSIS**
 ORGN Classifier
 Hominidae 86215
 Super Taxa
 Primates; Mammalia; Vertebrata; Chordata; Animalia
 Taxa Notes
 Animals, Chordates, Humans, Mammals, Primates, Vertebrates
 RN 39346-44-6 (**INTER-ALPHA-TRYPSIN
 INHIBITOR**)

Unable to pull
 Lkook 1/5/05